SCHEMBL3612969

SCHEMBL3612969

CC(=O)Nc1nnc(SCc2ccccc2)s1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.76
CYP1A2 P05177 1/20 0.76
CYP2C19 P33261 1/20 0.76
HTT P42858 1/20 0.76
ABL1 P00519 3/20 0.70
SRC P12931 3/20 0.70
RAB9A P51151 1/20 0.69
ALDH1A1 P00352 4/20 0.67
MEN1 O00255 4/20 0.67
KMT2A Q03164 4/20 0.67
KDM4E B2RXH2 2/20 0.67
GAA P10253 2/20 0.67
RECQL P46063 1/20 0.67
APOBEC3A P31941 1/20 0.67
APOBEC3G Q9HC16 1/20 0.67
ABCC8 Q09428 5/20 0.65
KCNJ11 Q14654 5/20 0.65
LMNA P02545 1/20 0.65
MAPT P10636 2/20 0.61
TSHR P16473 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8779364 0.88 SMN1; SMN2 (0.79) SMN1; SMN2CYP1A2CYP2C19HTTABL1
SCHEMBL8779340 0.86 CYP1A2 (0.77) SMN1; SMN2CYP1A2CYP2C19HTTABL1
SCHEMBL8779355 0.86 RAB9A (0.70) SMN1; SMN2ABL1SRCRAB9AALDH1A1
SCHEMBL8779366 0.85 ABL1 (0.84) SMN1; SMN2ABL1SRCRAB9AALDH1A1
SCHEMBL8779363 0.84 HTT (0.73) SMN1; SMN2CYP1A2CYP2C19HTTABL1
SCHEMBL8779385 0.84 MEN1 (0.58) SMN1; SMN2CYP1A2CYP2C19HTTABL1
SCHEMBL28451175 0.84 ABL1 (0.67) SMN1; SMN2CYP1A2CYP2C19ABL1SRC
SCHEMBL9018863 0.83 SMN1; SMN2 (0.72) SMN1; SMN2CYP1A2CYP2C19HTTABL1
SCHEMBL8779318 0.83 ABL1 (0.65) SMN1; SMN2ABL1SRCRAB9AALDH1A1
SCHEMBL8779378 0.82 ABL1 (0.70) SMN1; SMN2CYP1A2CYP2C19HTTABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0743574-B1 Migration imaging members XEROX CORP (US) 2000-12-27 EP claimed
EP-0743573-B1 Method for obtaining image contrast migration imaging members XEROX CORP (US) 2000-09-06 EP claimed
EP-0673784-B1 Recording sheets containing oxazole, isooxazole, oxazolidinone, oxazoline salts, morpholine, thiazole, thiazolidine, thiadiazole, and phenothiazine compounds XEROX CORP (US) 1999-10-27 EP claimed
EP-0579129-B1 Thiadiazole derivatives for the treatment of depressive states CT LAB FARM SRL (IT) 1997-03-05 EP claimed
EP-0579129-A2 Thiadiazole derivatives for the treatment of depressive states LABORATORIO FARMACEUTICO C.T. S.r.l. (IT) 1994-01-19 EP claimed
US-4810397-A ALUMINUM COMPOUND, ACID, THIADIAZOLE OR TRIAZOLE UNION OIL COMPANY OF CALIFORNIA (US) 1989-03-07 US claimed
US-4719001-A ALUMINUM COMPOUND AND THIADIAZOLE DERIVATIVE UNION OIL COMPANY OF CALIFORNIA (US) 1988-01-12 US claimed
US-9284287-B1 Compositions and methods for the suppression of carbonic anhydrase activity CELLIX BIO PRIVATE LIMITED (IN) 2016-03-15 US disclosed
US-20100029685-A1 OXADIAZOLE AND THIADIAZOLE COMPOUNDS AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS NEUROSEARCH A/S (DK) 2010-02-04 US disclosed
US-20100029685-A1 OXADIAZOLE AND THIADIAZOLE COMPOUNDS AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS NEUROSEARCH A/S (DK) 2010-02-04 US disclosed
US-20100029685-A1 OXADIAZOLE AND THIADIAZOLE COMPOUNDS AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS NEUROSEARCH A/S (DK) 2010-02-04 US disclosed
EP-2079734-A1 OXADIAZOLE AND THIADIAZOLE COMPOUNDS AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS NeuroSearch A/S (DK) 2009-07-22 EP disclosed
WO-2008049864-A1 OXADIAZOLE AND THIADIAZOLE COMPOUNDS AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS NEUROSEARCH A/S (DK) 2008-05-02 WO disclosed
WO-2008049864-A1 OXADIAZOLE AND THIADIAZOLE COMPOUNDS AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS NEUROSEARCH A/S (DK) 2008-05-02 WO disclosed
EP-0579129-B1 Thiadiazole derivatives for the treatment of depressive states CT LAB FARM SRL (IT) 1997-03-05 EP disclosed
US-5401853-A Thiadiazole derivatives for the treatment of depressive states LABORATORIO FARMACEUTICO C.T. S.R.L. (IT) 1995-03-28 US disclosed
EP-0579129-A2 Thiadiazole derivatives for the treatment of depressive states LABORATORIO FARMACEUTICO C.T. S.r.l. (IT) 1994-01-19 EP disclosed
US-4810397-A ALUMINUM COMPOUND, ACID, THIADIAZOLE OR TRIAZOLE UNION OIL COMPANY OF CALIFORNIA (US) 1989-03-07 US disclosed
US-4719001-A ALUMINUM COMPOUND AND THIADIAZOLE DERIVATIVE UNION OIL COMPANY OF CALIFORNIA (US) 1988-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029685-A1 OXADIAZOLE AND THIADIAZOLE COMPOUNDS AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS CHRNA3, CHRNA5, CHRNB3 SMN1; SMN2 274/4885CYP1A2 940/4885CYP2C19 1472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.